McKesson (MCK)
(Delayed Data from NYSE)
$485.42 USD
+3.15 (0.65%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$485.42 USD
+3.15 (0.65%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
Bruker (BRKR) Gains From New Product Bookings Amid Competition
by Zacks Equity Research
Bruker's (BRKR) revenue recognition from one gigahertz class NMR system and continued uptake of the timsTOF platform hold promise.
Walgreens Boots' (WBA) Product Expansion Aids Amid Rivalry
by Zacks Equity Research
Sales contributions from Walgreens Boots' (WBA) newly-formed Walgreens Health segment instill investors' optimism.
Here's Why Investors Should Retain Amedisys (AMED) Stock for Now
by Zacks Equity Research
Investors are optimistic about Amedisys' (AMED) better-than-expected earnings and notable buyouts.
PerkinElmer's (PKI) Reagent Kit Receives FDA Clearance
by Zacks Equity Research
PerkinElmer's (PKI) T-Cell Select reagent kit is expected to allow for a more automated workflow following the FDA's approval.
Is First Trust Consumer Staples AlphaDEX ETF (FXG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXG
The Zacks Analyst Blog Highlights NextEra Energy, Southern Company, PepsiCo, Corteva and McKesson
by Zacks Equity Research
NextEra Energy, Southern Company, PepsiCo, Corteva and McKesson are included in this Analyst Blog.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN's (QGEN) better-than-expected results and solid genomics uptake.
Abbott (ABT) Reports Favorable Findings From RELIEF Study
by Zacks Equity Research
The latest data from the RELIEF Study suggests a lower rate of hospitalizations from serious diabetes-related events with Abbott's (ABT) FreeStyle Libre system.
3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and solid prospects in the RCM space raise optimism about the stock.
Here's Why You Should Bet on ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies.
Here's Why You Should Buy McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Medtronic (MDT) Gets FDA's 510(k) Nod for Pediatric ICM
by Zacks Equity Research
This latest approval broadens Medtronic's scope within its Cardiovascular Diagnostics and Services wing within broader Cardiovascular business.
Bet on These 5 Ultra-Defensive Stocks for the Rest of 2022
by Nalak Das
We have narrowed our search to five low-beta high-yielding defensive stocks that have strong potential for the rest of 2022. These are: NEE, SO, PEP, CTVA and MCK.
Charles River (CRL) Gains From Growing Demand Amid Macro Woes
by Zacks Equity Research
Charles River (CRL) continues to expect that the growth rate will approach 20% in the second half of 2022.
McKesson (MCK) Stock Pares Gains Following Rx Savings Buyout
by Zacks Equity Research
McKesson (MCK) agrees to buy privately-held Rx Savings Solutions in alignment with its strategic plan of creating accessible and affordable treatment options.
Here's Why You Should Retain Stryker (SYK) Stock For Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.
Zimmer Biomet (ZBH) to Offer New Shoulder Replacement System
by Zacks Equity Research
Zimmer Biomet (ZBH) gets FDA nod for the Identity Shoulder System to help surgeons perform anatomic, reverse and revision shoulder replacement with precision.
Abiomed (ABMD) Posts Impellas Positive Study Results in Japan
by Zacks Equity Research
Abiomed's (ABMD) latest multi-center, multi-society study of Impella-supported patients is expected to significantly improve patient outcomes.
3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio
by Zacks Equity Research
PacBio's (PACB) strength in its Sequel system raises optimism about the stock.
Should You Invest in the First Trust Consumer Staples AlphaDEX ETF (FXG)?
by Zacks Equity Research
Sector ETF report for FXG
McKesson (MCK) Stock Moves -0.97%: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed the most recent trading day at $345.56, moving -0.97% from the previous trading session.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Higher production costs are a woe.
Quest Diagnostics (DGX) to Offer Lab Services for Lee Health
by Zacks Equity Research
Quest Diagnostics (DGX) inked a new agreement to deliver high-quality diagnostics services for a renowned healthcare provider in Southwest Florida.
Here's Why You Should Retain Boston Scientific (BSX) For Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) impressive top-line results and notable acquisitions.
Inari Medical (NARI) Posts Positive Results of FLASH Registry
by Zacks Equity Research
Inari Medical's (NARI) FlowTriever's latest favorable results are expected to significantly improve the treatment of PE.